Medicenna to Announce Fiscal Year 2022 Financial Results and Operational Highlights on Wednesday, June 22, 2022

Rhea-AI Summary

Medicenna Therapeutics Corp. (NASDAQ: MDNA) will hold a conference call on June 22, 2022, at 8:30 AM ET to discuss its fiscal year 2022 financial results and operational highlights. The call can be accessed at 1-877-407-9716 (Canada/US) or 1-201-493-6779 (international), using conference ID: 13729367. Medicenna focuses on immunotherapy, developing enhanced IL-2, IL-4, and IL-13 Superkines. Notably, their IL-2 Superkine, MDNA11, aims to improve cancer treatment by selectively targeting effector T cells and NK cells, while MDNA55 has advanced through multiple clinical trials.

Positive

• Medicenna will report fiscal year 2022 financial results, which could provide insights into company performance.
• MDNA55 has achieved Fast-Track and Orphan Drug status from the FDA and EMA, indicating potential for expedited development.

Negative

• None.

TORONTO and HOUSTON, June 07, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on June 22, 2022 at 8:30 AM ET to report its fiscal year 2022 financial results and operational highlights.

To access the call, please dial 1-877-407-9716 from Canada or the United States or 1-201-493-6779 internationally, followed by the conference ID: 13729367. To access the live webcast, please go visit https://viavid.webcasts.com/starthere.jsp?ei=1544577&tp_key=400e62120f. Following the live webcast, an archived version of the call will be available on Medicenna’s website.

About Medicenna
Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna’s early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna's IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.

FAQ

When will Medicenna report its fiscal year 2022 financial results?

Medicenna will report its fiscal year 2022 financial results on June 22, 2022, at 8:30 AM ET.

What is the focus of Medicenna's development efforts?

Medicenna is focused on developing immunotherapies, specifically novel IL-2, IL-4, and IL-13 Superkines.

What clinical trial status has MDNA55 received?

MDNA55 has obtained Fast-Track and Orphan Drug designation from the FDA and EMA.

How can I access Medicenna's conference call?

You can access the conference call by dialing 1-877-407-9716 from Canada or the US, or 1-201-493-6779 internationally, using conference ID: 13729367.